In a filing, Pliant Therapeutics Inc revealed its President and CEO Coulie Bernard unloaded Company’s shares for reported $0.59 million on Jan 17 ’25. In the deal valued at $11.20 per share,52,419 shares were sold. As a result of this transaction, Coulie Bernard now holds 430,517 shares worth roughly $4.7 million.
Then, Cummings Keith Lamont sold 20,148 shares, generating $225,680 in total proceeds. Upon selling the shares at $11.20, the Chief Financial Officer now owns 262,608 shares.
Before that, Hull Hans sold 15,936 shares. Pliant Therapeutics Inc shares valued at $178,501 were divested by the Chief Business Officer at a price of $11.20 per share. As a result of the transaction, Hull Hans now holds 211,558 shares, worth roughly $2.31 million.
A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Canaccord Genuity began covering PLRX with “Buy” recommendation on May 18, 2023. Robert W. Baird started covering the stock on April 13, 2023. It rated PLRX as “an Outperform”.
Price Performance Review of PLRX
On Tuesday, Pliant Therapeutics Inc [NASDAQ:PLRX] saw its stock fall -0.82% to $10.91. Over the last five days, the stock has lost -1.45%. Pliant Therapeutics Inc shares have fallen nearly -17.16% since the year began. Nevertheless, the stocks have fallen -36.61% over the past one year. While a 52-week high of $18.92 was reached on 01/03/25, a 52-week low of $10.22 was recorded on 01/23/25. SMA at 50 days reached $13.05, while 200 days put it at $12.86.
Levels Of Support And Resistance For PLRX Stock
The 24-hour chart illustrates a support level at 10.77, which if violated will result in even more drops to 10.62. On the upside, there is a resistance level at 11.07. A further resistance level may holdings at 11.22. The Relative Strength Index (RSI) on the 14-day chart is 36.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.65, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.73%. Stochastics %K at 8.95% indicates the stock is a buying.
How much short interest is there in Pliant Therapeutics Inc?
A steep rise in short interest was recorded in Pliant Therapeutics Inc stocks on 2025-01-15, growing by 0.32 million shares to a total of 7.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 7.22 million shares. There was a rise of 4.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 14, 2022 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.
